While clinical data are currently ongoing, preclinical studies involving PY314 have demonstrated that this anti-TREM2 therapy can provide anti-tumor activity in certain breast cancer models (EMT6) while improving the immune landscape of the TME through increasing the presence of CD8+ TILs, NK cells, and MHC-II-expressing TAMs [413]. This evidence concerns the gene TREM2 and breast cancer.